To effectively treat serious bone defects using bone regenerative medicine, there is a need for the development of a small chemical compound that potently induces bone formation.
The helioxanthin analogue (TH) is an osteogenic small compound that was first reported by Ohba
et al.
1) In their reports, TH not only stimulates osteoblast differentiation of osteoblast precursors, but also enhances bone regeneration in rodent bone defect models.
2,3) The osteogenic effects are also observed in mouse and human pluripotent stem cells
4,5) as well as human dental pulp stem cells.
6)